降压药物与痴呆及阿尔茨海默病风险:前瞻性队列研究个体参与者数据荟萃分析
未发现某一药物类别优于其他类别;
要点
- 未发现某一类降压药在降低痴呆风险上优于其他类别。
- 正常血压人群使用降压药与痴呆或阿尔茨海默病发病无关联。
核心结论
- 长期观察未发现特定降压药类别在降低痴呆风险上更有效。
- 在血压达高血压水平的人群中,使用任何有降压疗效的药物可能降低痴呆风险。
- 未来高血压管理临床指南应考虑降压药对痴呆风险的有益影响。
研究设计与样本
- 研究为个体参与者数据的荟萃分析,纳入1980年1月1日至2019年1月1日发表的前瞻性观察性研究。
- 纳入标准包括:前瞻性招募社区居住成人、样本量>2000、随访至少5年收集痴呆事件、测量血压并核实降压药使用、进行面对面检查辅以其他数据捕捉痴呆事件、随访死亡病例。
- 采用倾向评分控制与接受降压药治疗概率相关的混杂因素,研究特异性效应估计用随机效应荟萃分析合并。
主要发现
- 共发生3728例痴呆和1741例阿尔茨海默病。
- 未发现任一药物类别与所有其他类别在痴呆风险上有显著差异。
关键数值与推荐
- 高血压层定义:收缩压≥140 mm Hg或舒张压≥90 mm Hg。
- 正常血压层定义:收缩压<140 mm Hg且舒张压<90 mm Hg。
- 评估了五类降压药与痴呆及临床阿尔茨海默病的关联。
临床怎么用
- 对血压达高血压水平的55岁以上成人,使用任何有降压疗效的药物可能有助于降低痴呆风险。
- 选择降压药时,无需因痴呆预防目的而优先选用某一特定类别。
- 正常血压人群不应仅为预防痴呆而使用降压药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dementia is a major health concern for which prevention and treatment strategies remain elusive. Lowering high blood pressure with specific antihypertensive medications (AHMs) could reduce the burden of disease. We investigated whether specific AHM classes reduced the risk for dementia. METHODS: We did a meta-analysis of individual participant data from eligible observational studies published between Jan 1, 1980, and Jan 1, 2019. Cohorts were eligible for inclusion if they prospectively recruited community-dwelling adults; included more than 2000 participants; collected data for dementia events over at least 5 years; had measured blood pressure and verified use of AHMs; included in-person exams, supplemented with additional data, to capture dementia events; and had followed up cases for mortality. We assessed the association of incident dementia and clinical Alzheimer's disease with use of five AHM classes, within strata of baseline high (systolic blood pressure [SBP] ≥140 mm Hg or diastolic blood pressure [DBP] ≥90 mm Hg) and normal (SBP <140 mm Hg and DBP <90 mm Hg) blood pressure. We used a propensity score to control for confounding factors related to the probability of receiving AHM. Study-specific effect estimates were pooled using random-effects meta-analyses. RESULTS: Six prospective community-based studies (n=31 090 well phenotyped dementia-free adults older than 55 years) with median follow-ups across cohorts of 7-22 years were eligible for analysis. There were 3728 incident cases of dementia and 1741 incident Alzheimer's disease diagnoses. In the high blood pressure stratum (n=15 537), those using any AHM had a reduced risk for developing dementia (hazard ratio [HR] 0·88, 95% CI 0·79-0·98; p=0·019) and Alzheimer's disease (HR 0·84, 0·73-0·97; p=0·021) compared with those not using AHM. We did not find any significant differences between one drug class versus all others on risk of dementia. In the normal blood pressure stratum (n=15 553), there was no association between AHM use and incident dementia or Alzheimer's disease. INTERPRETATION: Over a long period of observation, no evidence was found that a specific AHM drug class was more effective than others in lowering risk of dementia. Among people with hypertensive levels of blood pressure, use of any AHM with efficacy to lower blood pressure might reduce the risk for dementia. These findings suggest future clinical guidelines for hypertension management should also consider the beneficial effect of AHM on the risk for dementia. FUNDING: The Alzheimer's Drug Discovery Foundation and the National Institute on Aging Intramural Research Program.
引用
- Ding J, Davis-Plourde KL, Sedaghat S, et al. Antihypertensive medications and risk for incident dementia and Alzheimer's disease: a meta-analysis of individual participant data from prospective cohort studies. Lancet Neurol. 2019. PMID: 31706889. doi:10.1016/S1474-4422(19)30393-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。